Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis

Neurology: Neuroimmunology and NeuroInflammation

Volumn 3, Issue 2, 2016, Pages

  Metz, Imke ^a   Beißbarth, Tim ^a   Ellenberger, David ^a   Pache, Florence ^b,c,d   Stork, Lidia ^a   Ringelstein, Marius ^e   Aktas, Orhan ^e   Jarius, Sven ^f   Wildemann, Brigitte ^f   Dihazi, Hassan ^a   Friede, Tim ^a   Brück, Wolfgang ^a   Ruprecht, Klemens ^b,c   Paul, Friedemann ^b,c,d  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b Department of Neurology ^*  (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^e Department of Orthopedic Surgery   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AQUAPORIN 1; AQUAPORIN 4; AQUAPORIN 4 ANTIBODY; AXONIN 1; CD71 ANTIGEN; CHITINASE 3 LIKE PROTEIN 1; EPSTEIN BARR VIRUS ANTIGEN 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERFERON; MYELIN ASSOCIATED GLYCOPROTEIN; NEUROFASCIN; NEUROFILAMENT PROTEIN; PEPTIDE; PEPTIDE ANTIBODY; PROTEIN NOGO A; PROTEIN S100B; PROTEOLIPID PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN ANTIBODY REACTION; ANTIGEN MICROARRAY; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MIMOTOPE MICROARRAY; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SELECTION MICROARRAY;

EID: 84999127547     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000204     Document Type: Article

References (40)

1. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202:473-477.
2. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85:177-189.
3. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6:805-815.
4. Kitley J, Leite MI, Kuker W, et al. Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies. JAMA Neurol 2013;70:1375-1381.
5. Waters P, WoodhallM, O'Connor KC, et al.MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm 2015;2:e89. doi: 10.1212/NXI.0000000000000089.
6. Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 2012;9:14.
7. Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 2014;261:1-16.
8. Quintana FJ, Farez MF, Viglietta V, et al. Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci USA 2008;105:18889-18894.
9. Van HK, Tomooka BH, Kidd BA, et al. Serum autoantibodies to myelin peptides distinguish acute disseminated encephalomyelitis from relapsing-remitting multiple sclerosis. Mult Scler 2013;19:1726-1733.
10. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-717.
11. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-1489.
12. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica (Devic's syndrome). Handb Clin Neurol 2014;122: 581-599.
13. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.
14. Jarius S, Probst C, Borowski K, et al. Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. J Neurol Sci 2010;291:52-56.
15. Beyer M, Nesterov A, Block I, et al. Combinatorial synthesis of peptide arrays onto a microchip. Science 2007; 318:1888.
16. Smyth GK, Yang YH, Speed T. Statistical issues in cDNA microarray data analysis. Methods Mol Biol 2003;224: 111-136.
17. Jung K, Becker B, Brunner E, Beissbarth T. Comparison of global tests for functional gene sets in two-group designs and selection of potentially effect-causing genes. Bioinformatics 2011;27:1377-1383.
18. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 2002;99: 6567-6572.
19. Bradl M, Misu T, Takahashi T, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009;66:630-643.
20. Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Papadopoulos MC. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2010; 133:349-361.
21. Wrzos C, Winkler A, Metz I, et al. Early loss of oligodendrocytes in human and experimental neuromyelitis optica lesions. Acta Neuropathol 2013;127:523-538.
22. Jarius S, Wildemann B. Aquaporin-4 antibodies (NMOIgG) as a serological marker of neuromyelitis optica: a critical review of the literature. Brain Pathol 2013;23: 661-683.
23. Yu X, Green M, Gilden D, Lam C, Bautista K, Bennett JL. Identification of peptide targets in neuromyelitis optica. J Neuroimmunol 2011;236:65-71.
24. Marnetto F, Hellias B, Granieri L, et al. Western blot analysis for the detection of serum antibodies recognizing linear Aquaporin-4 epitopes in patients with Neuromyelitis Optica. J Neuroimmunol 2009;217:74-79.
25. Long Y, Zheng Y, Shan F, et al. Development of a cell-based assay for the detection of anti-aquaporin 1 antibodies in neuromyelitis optica spectrum disorders. J Neuroimmunol 2014;273:103-110.
26. Schanda K, Waters P, Holzer H, et al. Antibodies to aquaporin-1 are not present in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm 2015;2:e160. doi: 10. 1212/NXI.0000000000000160.
27. Kitley J, Woodhall M, Waters P, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 2012;79:1273-1277.
28. Marignier R, Nicolle A, Watrin C, et al. Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury. Brain 2010;133:2578-2591.
29. Sabater L, Giralt A, Boronat A, et al. Cytotoxic effect of neuromyelitis optica antibody (NMO-IgG) to astrocytes: an in vitro study. J Neuroimmunol 2009;215:31-35.
30. Pohl M, Fischer MT, Mader S, et al. Pathogenic T cell responses against aquaporin 4. Acta Neuropathol 2011; 122:21-34.
31. Mitsdoerffer M, Kuchroo V, Korn T. Immunology of neuromyelitis optica: a T cell-B cell collaboration. Ann N Y Acad Sci 2013;1283:57-66.
32. Larsen PD, Bloomer LC, Bray PF. Epstein-Barr nuclear antigen and viral capsid antigen antibody titers in multiple sclerosis. Neurology 1985;35:435-438.
33. Ruprecht K, Wunderlich B, Giess R, et al. Multiple sclerosis: the elevated antibody response to Epstein-Barr virus primarily targets, but is not confined to, the glycinealanine repeat of Epstein-Barr nuclear antigen-1. J Neuroimmunol 2014;272:56-61.
34. Masuda S, Mori M, Arai K, et al. Epstein-Barr virus persistence and reactivation in neuromyelitis optica. J Neurol Neurosurg Psychiatry 2015;86:1137-1142.
35. Fraussen J, Claes N, de BL, Somers V. Targets of the humoral autoimmune response in multiple sclerosis. Autoimmun Rev 2014;13:1126-1137.
36. Reindl M, Rostasy K. MOG antibody-associated diseases. Neurol Neuroimmunol Neuroinflamm 2015;2:e60. doi: 10.1212/NXI.0000000000000060.
37. Zamvil SS, Slavin AJ. DoesMOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflamm 2015;2:e62. doi: 10.1212/NXI.0000000000000062.
38. Schirmer L, Srivastava R, Hemmer B. To look for a needle in a haystack: the search for autoantibodies in multiple sclerosis. Mult Scler 2014;20:271-279.
39. Ousman SS, Tomooka BH, van Noort JM, et al. Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination. Nature 2007;448:474-479.
40. Yeste A, Quintana FJ. Antigen microarrays for the study of autoimmune diseases. Clin Chem 2013;59:1036-1044.